TNF and rheumatoid arthritis: Recently, several promising biologic agents have been developed, and some have been identified as effective drugs for active RA with acceptable safety profiles.[3] They include tumor necrosis factor (TNF) inhibitors (etanercept, infliximab, adalimumab, and golimumab), a recombinant fusion protein modulating a co-stimulatory signal for T cell activation (abatacept), an interleukin (IL)6 receptor antagonist (tocilizumab), and a monoclonal antibody against CD20 (rituximab).